Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Deep brain stimulation

This article was originally published in The Gray Sheet

Executive Summary

Deep brain stimulation is "a treatment option" for patients suffering from Parkinson's disease with motor complications, new guidelines from the American Academy of Neurology suggest. The April 3 release of the guidelines was welcome news to Medtronic, which manufactures Activa, one of the deep brain stimulators on the market used to treat that condition. The firm is seeking to broaden the use of Activa to treat obsessive-compulsive disorder and depression (1"The Gray Sheet" April 4, 2005, p. 16)...

You may also be interested in...

Medtronic To Seek HDE For Activa To Treat Obsessive-Compulsive Disorder

Medtronic's pursuit of Activa deep-brain stimulation to treat chronic obsessive-compulsive disorder will serve as a springboard to the lucrative depression market, the company predicts

Oxford/AZ’s COVID-19 Vaccine Cuts Virus Spread By 60%

Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.

GemVax Aims For Alzheimer’s 'Game Changer' As Phase III Approaches

After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts